Immunoglobulins as a treatment modality for corticosteroid-refractory pemetrexed-induced interstitial lung disease, case report

Lucie Hordequin; Guillaume Eberst; Marc Guion-Dusserre; Anne Gondouin; Cindy Barnig; Virginie Westeel

doi:10.1016/j.resmer.2023.101000

Immunoglobulins as a treatment modality for corticosteroid-refractory pemetrexed-induced interstitial lung disease, case report

Respir Med Res. 2023 Jun:83:101000. doi: 10.1016/j.resmer.2023.101000. Epub 2023 Feb 20.

Authors

Lucie Hordequin¹, Guillaume Eberst², Marc Guion-Dusserre³, Anne Gondouin⁴, Cindy Barnig², Virginie Westeel²

Affiliations

¹ Service de Pneumologie, Centre Hospitalier Universitaire de Besançon, 3 Boulevard Fleming, Besançon 25030 CEDEX, France. Electronic address: lucie.hordequin@gmail.com.
² Service de Pneumologie, Centre Hospitalier Universitaire de Besançon, 3 Boulevard Fleming, Besançon 25030 CEDEX, France; UMR 1098, Université de Franche-Comté, Besançon, France.
³ Service de Pneumologie, Centre Hospitalier Universitaire de Dijon, Dijon, France.
⁴ Service de Pneumologie, Centre Hospitalier Universitaire de Besançon, 3 Boulevard Fleming, Besançon 25030 CEDEX, France.

PMID: 36812771
DOI: 10.1016/j.resmer.2023.101000

No abstract available

Keywords: Corticosteroid-refractory interstitial lung disease; Drug-induced ILD; Drug-induced respiratory disease; Intravenous immunoglobulins; Pemetrexed pulmonary toxicity.

Publication types

Case Reports
Letter

MeSH terms

Adrenal Cortex Hormones / therapeutic use
Humans
Immunoglobulins
Lung Diseases, Interstitial* / chemically induced
Lung Diseases, Interstitial* / drug therapy
Pemetrexed / adverse effects

Substances

Pemetrexed
Adrenal Cortex Hormones
Immunoglobulins